- PsiOxus Therapeutics Ltd has updated the agreement to advance its clinical collaboration with Bristol-Myers Squibb Co (NYSE: BMY) to evaluate PsiOxus' tumor re-engineering platform, in combination with BMY's Opdivo (nivolumab) to treat a range of tumor types.
- The first stage of this collaboration combined BMY's Opdivo with PsiOxus' enadenotucirev in Phase 1 SPICE study to evaluate the combination's safety and tolerability and optimize the combination intravenous dosing regimen.
- The revised collaboration will build upon the initial study data and will combine Opdivo with PsiOxus' NG-641.
- NG-641 is a tumor re-engineering product using PsiOxus' Tumor-Specific Immuno-Gene Therapy (T-SIGn) platform based upon the enadenotucirev vector.
- Under the terms of this agreement, PsiOxus will be responsible for conducting the Phase 1 study.
- Patient recruitment is expected to start in the third quarter of this year.
- Price Action: BMY shares are up 0.2% at $62.1 in the premarket trading on the last check Wednesday.
PsiOxus Therapeutics-Bristol Myers Expand Immuno-Oncology Collaboration
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.